PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the Health Canada approval of Sohonos (palovarotene capsules), an oral selective retinoic-acid receptor gamma ...
Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP) FOP impacts about ...
When Ipsen ponied up $1 billion in 2019 to acquire Clementia Pharmaceuticals for its rare disease drug palovarotene, the Paris-based company referred to the asset as “largely de-risked.” Four years, ...
Credit: Shutterstock. Ipsen has launched a patient support program to ensure access to Sohonos. The Food and Drug Administration (FDA) has approved Sohonos ™ (palovarotene) for reduction in the volume ...
Treatment indicated as the first and only for patients with fibrodysplasia ossificans progressiva. In a company press release, Ipsen revealed the FDA approval of Sohonos (palovarotene), indicated for ...
There is only one approved drug for ultra-rare disease fibrodysplasia ossificans progressiva (FOP) on the US market, but Regeneron is hoping to add to that tally. The US company has reported positive ...
PARIS, FRANCE, 16 August 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results